Highlights: Announced preliminary performance of MagSense® HER2 Imaging Agent in phase 1 study after study closure (post quarter end) Entered a strategic partnership with Prestige
Imagion’s CEO, Isaac Bright, presents our latest investor opportunities at ShareCafe’s Hidden Gems Webinar on 20 October 2023. https://youtu.be/XCfQ64VeVCg Video Transcript: First up, we have
Earlier this month, Imagion announced our upcoming EGM meeting to be held on 13th November, along with several resolutions to be voted on by shareholders. Here, Imagion
Highlights • Encouraging top-line performance of world’s first molecular MRI test • Pathology results from lymph node tissue shows concordance with MRI imaging MELBOURNE —
Notice is hereby given that an Extraordinary General Meeting (EGM) of Imagion Biosystems Limited (Imagion or Company) will be held at the offices of K&L
MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, is pleased to provide highlights from
We’re on a mission to make cancer more detectable.